Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0A3CL
|
||||
| Former ID |
DIB001791
|
||||
| Drug Name |
AZD1979
|
||||
| Indication | Obesity [ICD9: 278; ICD10:E66] | Phase 1 | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Target and Pathway | |||||
| Target(s) | Melanin-concentrating hormone receptor 1 | Target Info | Modulator | [2] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
| Reactome | Peptide ligand-binding receptors | ||||
| G alpha (q) signalling events | |||||
| G alpha (i) signalling events | |||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT02072993) A First Time in Man Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1979 in Healthy Males. U.S. National Institutes of Health. | ||||
| REF 2 | Phase I clinical trial of AZD1979 for treating obesity. AstraZeneca plc | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.